Kela to provide reimbursement for fertility treatments again
21.3.2025 07:52:45 EET | Kela/FPA | Press release
Parliament has approved the reintroduction of Kela reimbursement for fertility treatments administered by private healthcare providers. The amendment will enter into force on 1 May 2025. The aim is to improve the status of individuals and couples who have been unable to conceive due to medical reasons.
Parliament has approved the introduction of Kela reimbursement for fertility treatments administered by private healthcare providers.
Kela will start to provide reimbursement for the costs of fertility treatments as of 1 May 2025 in cases where infertility is caused by a medical condition and the applicant is under the age of 43. If the applicant is older than this, Kela will assess on a case-by-case basis whether reimbursement can be granted, basing its decisions on medical statements.
Reimbursement will be available for medical examinations and treatments performed or prescribed by a gynaecologist or an obstetrician in the context of fertility treatments. Reimbursement will not be available for fertility treatments administered for reasons other than a medical condition.
The aim is to give people who need fertility treatments due to medical reasons better access to treatment in private healthcare, where the age limits for treatment may be higher than in public healthcare. This will give more people access to fertility treatments, which may, in turn, help boost birth rates.
Kela’s list of reimbursement rates shows the amount and grounds for reimbursement
Reimbursement will be granted only for medical examinations and treatments conducted as part of fertility treatments, but not for any administrative or processing fees, Kanta fees or clinical or outpatient fees.
The grounds and maximum amounts of reimbursement (i.e. reimbursement rates) are set down by government decree. Kela confirms the reimbursement rates and publishes a list of the rates.
"Kela has previously reimbursed costs incurred for fertility treatments, most recently in 2022. At the time, Kela reimbursed about 13% of the cost of the treatments, and reimbursements were paid to 6,622 people. This time around, the reimbursement rate will be significantly higher than in 2022," says Merja Larikka, Senior Coordinator.
Reimbursement also available for medication and travel
Kela grants reimbursement for the costs for medication used in fertility treatments when infertility is due to a medical condition and the medication is covered by the reimbursement system. The conditions for reimbursement are that the medication has been prescribed to a person under the age of 43 and that the reimbursement status of the medication has been confirmed by the Pharmaceuticals Pricing Board and is valid. Reimbursement may be granted on a case-by-case basis to persons aged 43 or over, on the basis of a medical statement.
Following the amendment, Kela will grant reimbursement for travel costs incurred in connection with fertility treatments administered by private healthcare providers if the treatment provided is also subject to reimbursement from Kela.
Contacts
Riikka PalomäkiBenefits ManagerKela
Tel:050 435 1763firstname.lastname@kela.fiMerja LarikkaSenior CoordinatorKela
Tel:050 470 0630firstname.lastname@kela.fiKela's Communications UnitFor media enquiries, please contact us between 9:00 and 16:00, Monday to Friday. This number can be used for interview requests, which we will be happy to forward to an appropriate source at Kela. You can also submit interview requests by email.
Tel:+358 20 634 7745viestinta@kela.fiAlternative languages
Subscribe to releases from Kela/FPA
Subscribe to all the latest releases from Kela/FPA by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Kela/FPA
Betydligt fler pojkar börjar behandling med adhd-läkemedel i Finland än i grannländerna5.10.2026 06:00:00 EEST | Pressmeddelande
Andelen pojkar i åldern 6–8 år som började behandling med adhd-läkemedel vände åter till en svag ökning under 2025. Antalet personer som börjar läkemedelsbehandling har mer än fördubblats sedan 2017, och siffrorna i Finland verkar ha stabiliserats på en betydligt högre nivå än i grannländerna. Skillnaderna mellan välfärdsområdena är stora.
Pikkupoikien ADHD-lääkityksen aloittaminen on asettunut huomattavasti korkeammalle tasolle kuin naapurimaissa5.10.2026 06:00:00 EEST | Tiedote
Läs meddelandet på svenska (fpa.fi). ADHD-lääkityksen aloittaneiden osuus 6–8-vuotiaista pojista kääntyi uudelleen lievään kasvuun vuonna 2025. Aloitusten määrä on yli kaksinkertaistunut vuodesta 2017, ja Suomen luvut näyttävät asettuneen naapurimaita merkittävästi korkeammalle tasolle. Hyvinvointialueiden väliset erot ovat suuria.
Pikkupoikien ADHD-lääkityksen aloittaminen on asettunut huomattavasti korkeammalle tasolle kuin naapurimaissa5.10.2026 06:00:00 EEST | Tiedote
ADHD-lääkityksen aloittaneiden osuus 6–8-vuotiaista pojista kääntyi uudelleen lievään kasvuun vuonna 2025. Aloitusten määrä on yli kaksinkertaistunut vuodesta 2017, ja Suomen luvut näyttävät asettuneen naapurimaita merkittävästi korkeammalle tasolle. Hyvinvointialueiden väliset erot ovat suuria.
Korrigerat pressmeddelande: FPA ber cirka 25 000 studerande lämna in en utredning om varför studierna inte framskridit tillräckligt – studiestöd och bostadstillägg kan dras in för en del2.10.2026 15:06:09 EEST | Pressmeddelande
FPA följer årligen upp studietakten hos studerande på andra stadiet och hos högskolestuderande. En studerande ska göra tillräckliga framsteg i sina studier för att FPA ska kunna betala ut studiestöd och bostadstillägg.
Korjattu tiedote: Kela pyytää noin 25 000 opiskelijalta selvitystä siitä, miksi opinnot eivät ole edistyneet – opintotuki ja asumislisä voidaan lakkauttaa osalta2.10.2026 15:06:09 EEST | Tiedote
Läs meddelandet på svenska (fpa.fi). Pressrelease in English (kela.fi). Kela seuraa vuosittain, etenevätkö toisen asteen ja korkeakoulujen opiskelijat opinnoissaan riittävästi. Opiskelijan täytyy edetä opinnoissaan riittävästi, jotta Kela voi maksaa opintotukea ja asumislisää.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom